Literature DB >> 8528601

Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines.

U Lippert1, S Krüger-Krasagakes, A Möller, U Kiessling, B M Czarnetzki.   

Abstract

Mast cells and basophils are central effector cells of allergic reactions and are involved in inflammatory diseases. These cell types produce an array of mediators including a broad spectrum of cytokines. In order to examine whether antiallergic drugs modulate the release of these mediators, we have investigated the influence of dexamethasone and decarboethoxy-loratadine (DEL), the active metabolite of the H1-blocking agent loratadine, on the release of IL-6 and IL-8 by the human mast cell line HMC-1 and the human basophilic cell line KU812 by ELISA. Dexamethasone (10(-6)-10(-11) M) or Del (10(-5)-10(-14) M) were added to the cells either 1 h prior to or simultaneously with PMA and Ca-ionophore A23187. When preincubated with the cells, DEL dose-dependently suppressed IL-6 release by up to 40% and IL-8 release by up to 50%. Dexamethasone potently suppressed secretion of both cytokines if simultaneously added to the cells with the stimuli by up to 60% and after preincubation by up to 80%. Since both antihistamines and glucocorticoids are used for treatment of allergic diseases, the findings reported here indicate that these drugs may modulate allergic reactions via inhibition of cytokine release from mast cells and basophils.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528601     DOI: 10.1111/j.1600-0625.1995.tb00257.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

Review 1.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.

Authors:  Viktoria Ferencz; Szilvia Meszaros; Emoke Csupor; Edit Toth; Katalin Bors; Andras Falus; Csaba Horvath
Journal:  Osteoporos Int       Date:  2006-01-24       Impact factor: 4.507

3.  Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.

Authors:  Zhen Qin; Chao Chen
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

4.  Desloratadine.

Authors:  K McClellan; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.

Authors:  Greg W Bensch; Harold S Nelson; Larry C Borish
Journal:  Ann Allergy Asthma Immunol       Date:  2002-05       Impact factor: 6.347

Review 6.  Allergic rhinitis and asthma in children: disease management and outcomes.

Authors:  C E Baena-Cagnani
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

Review 7.  Desloratadine: an update of its efficacy in the management of allergic disorders.

Authors:  David Murdoch; Karen L Goa; Susan J Keam
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.

Authors:  Tong-Jun Lin; Lauren H Maher; Kaede Gomi; Jeffrey D McCurdy; Rafael Garduno; Jean S Marshall
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 9.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].

Authors:  S Schulz; M Metz; D Siepmann; T A Luger; M Maurer; S Ständer
Journal:  Hautarzt       Date:  2009-07       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.